Somatic mutations are postzygotic mutations which may lead to mosaicism, the presence of cells with genetic differences in an organism. Their role in cancer is well established, but detailed investigation in health and other diseases has only been recently possible. This has been empowered by the improvements of sequencing techniques, including single-cell sequencing, which can still be error-prone but is rapidly improving. Mosaicism appears relatively common in the human body, including the normal brain, probably arising in early development, but also potentially during ageing. In this review, we first discuss theoretical considerations and current evidence relevant to somatic mutations in the brain. We present a framework to explain how they may be integrated with current views on neurodegeneration, focusing mainly on sporadic late-onset neurodegenerative diseases (Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis). We review the relevant studies so far, with the first evidence emerging in Alzheimer's in particular. We also discuss the role of mosaicism in inherited neurodegenerative disorders, particularly somatic instability of tandem repeats. We summarize existing views and data to present a model whereby the time of origin and spatial distribution of relevant somatic mutations, combined with any additional risk factors, may partly determine the development and onset age of sporadic neurodegenerative diseases.
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Background and theoretical considerations
Mutations are termed 'somatic' if they occur postzygotically, and can lead to mosaicism, the presence of genetically different cells within a single organism [1, 2] . Somatic mutations underlie antigenic variation, and have long been linked to cancer, with decades of studies and technological advances supporting and elucidating their role [3] . The latest advances in DNA sequencing have shown mosaicism to be more prevalent than previously thought in humans [2, [4] [5] [6] , whether arising in development or ageing, with the term 'somatic evolutionary genomics' used to describe the study of the accumulation of somatic mutations in the body [7] . Somatic mutations can indeed be used to reconstruct the developmental cell lineage in an organism [7, 8] . Mosaicism can be classified as somatic (affecting the 'soma', or body), gonadal (affecting the germline) and gonosomal (affecting both) [5] . Somatic and gonosomal mosaicism could affect the nervous system, but only gonadal and gonosomal are heritable. Indeed, an important recent realization with profound implications in genetic counselling, is that apparently 'de novo' mutations in a patient can actually reflect gonadal or gonosomal mosaicism in a parent [9] . Studying this is obviously easier in sperm than ova, with striking sperm mosaicism recently reported [10] .
The existence of somatic mutations in apparently healthy nervous system tissues, and a possible role in non-neoplastic neurological disease, have only been explored relatively recently. The evidence for a role of somatic mutations in a wide range of neurodevelopmental and neuropsychiatric disorders is already strong [11] . A role of somatic mutations in neurodegenerative diseases has been repeatedly hypothesized [7, [12] [13] [14] . In this review, we discuss the theoretical basis and current evidence for somatic mutations in neurodegeneration, focusing on the common, mainly sporadic, lateonset neurodegenerative diseases such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB), Alzheimer's disease (AD) and amyotrophic lateral sclerosis/frontotemporal lobar degeneration (ALS/FTLD) spectrum. Somatic mutations may represent good candidates to explain some of the main features of these illnesses, such as sporadic occurrence, focal onset and progressive spread of the pathology [15] . We will also discuss rare and inherited conditions, including mixed neurodevelopmental and neurodegenerative disorders, where relevant.
Genetic variation between individuals can occur due to several broad classes of mutations: single-nucleotide variants (SNVs) and indels (small insertions/deletions), copy number variants (CNVs) and other structural variants (SVs), tandem repeats such as trinucleotides, L1 retrotransposons and other transposable elements (TEs) and aneuploidy. All these types of variations can also occur somatically, leading to mosaicism [6] , and have now been reported in normal brain [11] . We use the term somatic mutation to refer to any acquired postzygotic change in the nuclear genome, from single base to whole chromosome, encompassing all the above. Broadly, aneuploidy arises from spindle errors in cell division, TE insertions arise from their retrotransposition activity, whereas other mutations arise during either DNA replication, or repair of DNA damage (single-strand breaks (SSBs) and double-strand breaks (DSBs)) [16, 17] . DNA damage may lead to transient chemical lesions, but if they are erroneously repaired, a somatic mutation will result [18] .
In its broader definition, mosaicism can be considered to result from epigenetic changes rather than mutations [1] . There is also the special case of mitochondrial DNA (mtDNA), which is highly variable between, and even within, cells (heteroplasmy). Although these are both beyond the scope of this review, we should note that a role of mtDNA mutations in neurodegeneration, particularly deletions in PD, has been repeatedly claimed, with the latest evidence suggesting accumulating deletions and relative depletion of normal mtDNA are most relevant [19] .
Are somatic mutations likely to be common, and could they confer an early selective advantage?
The 'disposable soma' theory postulates that less effort will be invested in maintenance of an organism, than in securing it achieves reproduction [20] . Extrapolating this concept to mutations, one might expect a higher somatic than germline mutation rate. Indeed this was recently demonstrated for SNVs in both humans and mice, with a human somatic mutation rate of 2.66 9 10 À9 per base per mitosis in fibroblasts [21] .
With a minimum number of cell divisions estimated at 10 13 to 10 14 [7] , this would lead to each base mutating several thousand times, and each cell could have hundreds of deleterious mutations [22] . As these estimates exclude other mutation types, and have not been performed in rapidly proliferating neuronal precursors, the total burden of somatic mutations in neurons could be even higher.
Although somatic mutations in a normal brain might appear at first to only have negative consequences, they have been proposed to confer advantageous diversity [23] [24] [25] . It was first suggested half a century ago that a form of 'chromosomal programming', analogous to the immune system recombination of antibody-coding genes, might underlie the extreme diversity and specialization of neurons [26] , and later that neurons may pass through a stage when they are particularly sensitive to DNA DSB [27] . DSB in mouse neuronal precursors were first reported almost 20 years ago [28] , and recently demonstrated conclusively, mostly in genes involved in synaptic function or neural cell adhesion [29] . A specific developmental 'window' for sensitivity to DNA damage in vivo has now been demonstrated in mouse enteric neuronal cells [30] . Neuronal precursors therefore join lymphocytes as cells with naturally high rates of localized DSB, providing a mechanism for generation of mosaicism in early embryogenesis [31] , although distinct from the mechanism of immunoglobulin gene rearrangements [27] .
A particular issue in the developing nervous system is competition for survival from apoptotic programmed cell death of both neuroblasts and postmitotic neurons [27] . It appears unlikely that cells which ultimately survive are selected randomly, as 'an advantage must be conferred on them by genetic differences' [32] , with somatic mutations a possible substrate for positive and negative selection [27] . Somatic mutations arising exclusively in embryonic neurogenesis should have a stable level in ageing postmitotic neurons, unless they impact neuronal survival. There are several possible reasons, however, why they might increase with age [33, 34] . Oxidative stress, which increases with age, could cause mutations by errors in DNA repair. Aberrant cell cycle re-entry as a protective mechanism could trigger large-scale DNA gains. Transcriptionrelated DNA damage could also lead to mutations in postmitotic neurons. A fascinating study showed that neuronal activity can lead to DSB in mice [35] . Such events might be limited to single neurons individually, but common collectively. Finally, mutagenesis in adult brain neurogenesis is unexplored.
Evidence for existence of somatic mutations in healthy brain
The field is evolving so rapidly that we feel an overview of the current state is warranted. Aneuploidy has been traditionally studied using fluorescence in situ hybridization (FISH) or its chromogenic equivalent (CISH), which can visualize single nuclei directly. DNA analysis has been revolutionized by 'next-generation' sequencing, whether targeted or whole genome. Traditionally, DNA is extracted from the tissue of interest, and this 'bulk' DNA is analysed. One obvious limitation is the level at which a somatic mutation of any type is present, as it may be difficult to distinguish it from background. In addition, DNA extraction can lead to significant GCdependent bias, which may confound determination of subtle copy number differences [36, 37] . DNA quality and results could also be affected by premorbid factors like hypoxia, which leads to brain DNA fragmentation particularly in elderly rats [38] , and post mortem interval. Interpretation of data from fixed paraffin-embedded (rather than frozen) specimens may require additional attention [39] . Single-cell sequencing has revolutionized somatic mutation studies [40] . Whole-genome sequencing (WGS) after whole-genome amplification (WGA) of single cells is now possible, and the amplification, sequencing and analysis protocol can be geared towards the type of variant of interest. The main issues related to this method, apart from cost limiting the sequencing 'depth' or 'coverage', and the number of cells, are efficient cell characterization and isolation, and accurate and even amplification of single-cell DNA, which is influenced by the WGA method chosen [11, 40] .
Aneuploidy (the gain or loss of chromosomes) was the first type of mosaicism described in mouse brain, where one-third of neuroblasts appear aneuploid [41] , due to chromosome segregation defects [42] and later in adult humans [43] . A mean aneusomy (aneuploidy rate per chromosome) of 0.1-0.8% was found in post mortem adult neurons [44] , and >1% in foetal brain [45] . Neuronal aneusomy for chromosome 21 was estimated at 4% [43] and~12% [46] . Single-cell sequencing studies have confirmed the existence of aneuploidy in healthy human brains, but at apparently lower rates, with overall aneuploidy 0.7%-5% in single frontal neurons [47] [48] [49] , and 2.2% in unselected cells from frontal lobe grey matter [50] . The higher frequency of aneuploid neuroblasts suggests selection against them, and this was indeed demonstrated in a mouse study where inhibition of programmed cell death led to a marked rise of aneuploid cells, with increased levels of 'extreme' aneuploidies [51] .
CNVs are gains or losses of DNA fragments (size cutoff defined variably as 50 bases -1 kb). Several WGS studies, mostly of single control frontal cortical neurons, showed individual neuronal CNVs as aberrations in read depth at very low coverage WGS (<1x) [47, 48, 52, 53] , although one which looked for CNVs as a secondary aim did not find any definitive evidence [24] (Table 1) . Only large (megabase-scale) CNVs were detectable, except for a study using a microfluidic platform, which minimized WGA variability and called smaller CNVs, mostly gains [52] . Importantly, reanalysis of data with other algorithms can lead to fewer CNV calls [53, 54] , highlighting the pitfalls of current methods. Some CNVs were shared between cells, suggesting a developmental origin [47, 53, 55] . In addition to simple CNVs, various types of structural variants (SVs) exist, and translocations or inversions can occur alone, not leading to CNVs, or combined with copy number changes in complex patterns. The complexity of inherited SVs is becoming increasingly evident [56] , and their origins can be traced back to processes known as chromothripsis and chromoanasynthesis [57] , first described in cancer. A remarkable cloning study generated viable mice from single olfactory neurons, and thus allowed robust calling of SVs and other mutations, free of WGA artefacts [58] . An average of 1.5 SV per neuron were reported, of which onethird were complex, suggesting chromothripsis. Most were very small (seven of nine <35 kb), but the cloning protocol may have selected against neurons with larger genomic abnormalities. The SV origin was felt most likely to be postmitotic.
L1 retrotransposition is the insertion of mobile LINE-1 (L1) elements in a new genomic location. L1 elements comprise one-sixth of the human genome, and can 'copy-paste' themselves back into new positions in the genome, leading to somatic L1 insertions [59] . Retrotransposition activity was demonstrated in neuronal precursor final divisions [60] , and it may also occur in postmitotic neurons [61] . Somatic insertions were detected in adult human brain [62] , and confirmed in several single-cell studies, mostly reporting <1 insertions per human neuronal genome [63] [64] [65] , and a similar frequency in glia [65] , and mouse olfactory neurons [58] . Hippocampal neurons may each have 13.7 L1 insertions [24] , although reanalysis by another group suggested a true positive rate~0.2 per neuron [66] . While the frequency may vary between neuronal types, and analysis methods require standardization, it is clear that L1 brain mosaicism does exist.
DNA content variation (DCV) may occur in individual neurons, with frontal neurons having up to 250 Mb extra DNA compared to cerebellar neurons or lymphocytes from the same healthy individual [67] . This phenomenon affects~11.5% of neurons, with no difference across cortical regions, and the frequency of neurons with increased DNA content declining with age [68] . This effect was not noted in another study, although the data suggest a possible similar trend in nondiseased prefrontal cortex and cerebellar neurons [69] . This suggests that neurons with higher DNA content may be preferentially prone to loss in ageing. DCV could be due to gains arising through a variety of mechanisms, including aneuploidy, CNVs and L1 or other TE insertions. The low prevalence of aneuploidy and somatic L1 insertions make them unlikely to be major contributors, and the predominance of gains in one single neuron CNV study may be relevant [52] .
SNVs ('point mutations') may be the commonest somatic variants in normal brains [11] . Deep WGS of single control frontal cortical neurons revealed~1500 somatic SNVs in each (80% C>T transitions) [70] . The subsequent study of cloned mouse olfactory neurons estimated <100 SNVs per neuron (40% C>T) [58] . These SNVs may arise postmitotically [58, 70] , leading to the question of whether they increase with age, although the typical signatures of mutations arising from aberrant repair after oxidative stress were not seen [58] . Very recent work by the same group showed increasing single neuron SNVs with age in prefrontal cortex and hippocampus [71] . This is consistent with a study using WGS of 'bulk' DNA, with modifications of the library preparation to detect low level mutations, which reported >1 somatic SNV per 10 million bases in frontal cortex from children, rising six-fold in older adults [72] . One concern has been the abundance of C>T changes, which can arise by chemical modification of DNA [22, 73] . They were, however, shown to vary with age, suggesting a biological cause [71] .
Distribution of brain somatic mutations depends on when they arise (Figure 1 ). Those arising in very early development, before the germ layers split in gastrulation, might be detectable in a wide range of tissues, including blood, albeit at possibly very low levels [14, 15] . Indeed, somatic SNVs present in >5-10% of brain cells were also found outside the brain, including in tissues derived from mesoderm and endoderm [70] . After gastrulation, somatic mutations affecting [53] Obtained from dissociated cortical grey matter. High-quality cells only included.
Frontal cortical neurons from healthy individuals, selected by sorting with NeuN, unless specified otherwise.
brain tissues would be restricted to the ectodermal lineage, but even at this stage they could be widely dispersed throughout the nervous system. It has become clear that there is profound mixing of neuronal cells in very early development, with an example of a somatic SNV found throughout the cerebral cortex, cerebellum and spinal cord [70] . Mutations occurring later, but still in dividing neuronal precursors, would reach a lower level and be restricted to a smaller brain region, with examples of such SNVs and L1 insertions also demonstrated [64, 70] . Postmitotic mutations should be confined to one cell, but could be common collectively.
Rationale for a role of somatic mutations in neurodegeneration
The commonest neurodegenerative diseases (AD, PD, ALS) are generally sporadic, but inherited cases due to mutations in several genes are well described. These genes are prime candidates for somatic mutations leading to sporadic cases, possibly with milder phenotypes [74] . This would be analogous to hypertension caused by primary aldosteronism, where somatic mutations lead to milder phenotypes than inherited [75] . Notably, inherited mutations in several genes do lead to earlier onset than sporadic disease, for example SNCA and recessive genes in PD [76, 77] , APP and particularly PSEN1 in AD [78] , and FUS, SOD1 and genes of juvenile forms in ALS [79] . It appears likely that an individual somatic mutation could only have a significant effect if it arose early enough to be present in a substantial proportion of cells of the relevant type. The actual level needed in a region or cell type to contribute to neurodegeneration is completely unknown. Accumulating evidence suggest the importance of spread of pathology in neurodegenerative disorders [80] . If a somatic mutation were responsible, it could be a local trigger that leads to spread from a small number or even a single mutant cell [7, 15, 81] . Alternatively, widespread somatic mutations, even at low levels, could increase individual cell vulnerability to a spreading agent. Conversely, or additionally, other factors, such as intrinsic neuronal type vulnerability, may be important in pathology development, at least in PD [82] [83] [84] , which may have multifocal onset [85] . Could somatic mutations have a role in such a scenario? Clearly this could not be a localized mutation [86] , but there are two nonmutually exclusive possibilities. Somatic mutations arising independently in many locations could affect the 'threshold' for disease development. Alternatively, a single mutation in early embryogenesis could 'spread' to multiple tissues, even if spatially separated, if their lineage is shared, for example in PD where multiple neural crestderived structures may be affected early [14] . The pattern of dispersed somatic mutations could determine the clinical and pathological phenotype, for example with SNCA mutation distribution determining a predominantly PD or DLB picture, with variable peripheral involvement, or indeed multiple system atrophy (MSA) if the glia and autonomic system were more affected. Somatic mutations may also affect penetrance of inherited mutations, including in discordant monozygotic twins [70] , such as a twin pair with LRRR2 G2019S mutation discordant for PD [87] . Figure 1 . Distribution of somatic mutations depending on timing of origin. In this highly simplified view of development, a zygote, outer view of a blastocyst (day 4), and the trilaminar disc where the three germ layers separate (day 16), are shown. Squares with different colours represent mutations which may be shared between several tissues. Green squares may be present in cells derived from all three germ layers. Blue squares will be restricted to ectodermal-derived tissues, red squares to mesodermal and orange squares to endodermal, although they may not be present in all tissues from that germ layer. Triangles are later mutations, restricted to a specific tissue type. A 'green square', 'blue square' and 'purple triangle' mutation can all affect the brain, but they will be potentially detectable in all other tissues, ectodermal tissues only, and nervous system only, respectably. Green squares may lead to gonosomal mosaicism, blue and orange squares and red triangles will lead to somatic mosaicism only, and pink triangles in the germline will lead to germline mosaicism only.
A significant role of somatic mutations in sporadic neurodegenerative diseases appears more likely if the following conditions are met.
(1) Increased somatic mutability of genes involved in sporadic neurodegenerative diseases Fragile sites are genomic regions prone to damage particularly during DNA replication stress, where somatic CNVs may arise [88, 89] . Two key genes causing inherited PD, SNCA and PARK2, are within common fragile sites [90, 91] , although it is not known if they are fragile in neuroblasts. A gain of several megabases across that fragile site, including SNCA, was indeed reported in 1/110 frontal neurons from controls [47] . In addition, PARK2 is unstable in various cancers, including melanoma [92] . Furthermore, somatic L1 insertions in both these genes were reported in caudate neurons from controls [62] . GBA, a major genetic risk factor in PD and DLB, has a highly homologous nearby pseudogene, which results in SV caused by aberrant recombination. Although there are no such known somatic events, we hypothesize that they may occur, and could account, for example for the loss of glucocerebebrosidase enzymatic function in PD patients not carrying inherited mutations [93] . (2) Increased tendency of patients with sporadic neurodegenerative diseases to somatic mutations in general A generalized tendency to develop somatic mutations might be detectable in other tissues, perhaps even blood. Studies of DNA damage in response to UV radiation in lymphoblasts showed that PD and AD-derived lines, but not ALS, were more sensitive than controls [94, 95] . Micronuclei, nuclear structures where chromothripsis may occur [96] , were found more often in peripheral blood leucocytes (PBL) from PD and AD than controls [97] . The increased occurrence of melanoma in PD remains unexplained, with melanocytes sharing a neural crest origin. Melanocytes from individuals with inherited risk of PD may have genomic instability predisposing to both, with UV damage triggering melanoma more readily [98] . (3) Conferring a selective advantage in development Several neurodegenerative disease genes have important roles in early neurodevelopment, for example SNCA, which regulates the synaptic vesicle pool [99] , and APP, which increases axonal growth cone size when overexpressed [100] . One can therefore speculate the existence of somatic mutations beneficial to the developing neuron, but predisposing to protein aggregation and neurodegeneration in the ageing brain [14] ('antagonistic pleiotropy' [101] ).
Evidence for a role of somatic mutations in neurodegeneration
Synucleinopathies (Parkinson's disease, dementia with Lewy bodies, multiple system atrophy)
Limited work has been done to investigate mosaicism in synucleinopathies. We analysed SNCA coding exons in at least one brain region in over 500 cases of PD and DLB using a PCR-based assay, able to detect SNVs present at levels of at least 5-10% [14, 102] (Table 2 ), but did not find any. Early studies investigated genome-wide CNV mosaicism using microarrays. One found some specific to PD brains, but they were not independently confirmed, and did not involve PD genes [103] . An interesting study of PBL from monozygotic twins discordant for PD/DLB showed different postzygotic CNVs, but again none involved PD genes, and no brain tissue was analysed [104] . One very large mosaic duplication involving SNCA was reported in PBL of a 69-year old case, which appears likely pathogenic, but again no brain tissue was available [105] . An interesting study claimed high level mosaicism for SNCA gains in ectodermal cells from the oral mucosa in two early onset cases based on FISH [106] , but another assay (multiple ligation probe amplification, MLPA) was negative, even in the case with apparent 75% mosaicism, and no brain was available.
Mosaicism for large-scale genomic changes was investigated in three studies. One group reported mosaic aneuploidy (gains for both chromosomes studied) in PD nigra neuromelanin-positive neurons, and proposed aberrant DNA synthesis leading to whole genome duplication [107] . Another study assessed DCV in neurons selected by NeuN; in Lewy body diseases, several cell types, including nigral pigmented neurons, had higher DNA content than controls [108] . Interestingly, the same group did not find DCV in MSA [109] .
Alzheimer's disease
Three different targeted studies of brain DNA are summarized in Table 2 . A single case of a somatic SNV apparently directly causing AD (a missense mutation in PSEN1) has been reported [110] . Interestingly, this was only detected because it was transmitted to the offspring, who was therefore heterozygous for the mutation, and developed a severe phenotype. The level of the mutation in the mosaic parent was 14% in cerebral cortex and 8% in PBL. Although the germline DNA was not available, the parent clearly was a gonosomal mosaic. The phenotype was milder in the mosaic, as discussed earlier [74] . The mutation must have arisen very early in embryogenesis, leading to gonosomal mosaicism (see Figure 1) .
A later systematic study using very high coverage sequencing of AD genes in entorhinal cortex from sporadic cases and controls, focusing primarily on SNVs, detected three somatic mutations at~1% level, but none in the most relevant genes in patients [111] . Two of these were novel missense mutations in MAPT, likely to be damaging, in patients, whereas the third was a known PSEN2 variant in a control. The study had a low validation rate (3/107), illustrating the difficulties in detecting low level SNVs in 'bulk' DNA. No evidence of mosaic gains in APP or other AD genes was found, but sensitivity was estimated at 10% or more of cells having a gain [111] . A study using multiple methods, including single-cell analysis, found somatic gains in APP in AD prefrontal cortical neurons, with up to 12 copies per cell [69] . The mean copy number, assessed by single-cell qPCR for two different exons, was 3.8 and 3.4 copies for AD cortical neurons, compared to 1.6 and 1.44 for controls (with cerebellar neurons around 2). A recent single neuron WGS study did not detect APP gains in AD [49], but it was designed for aneuploidy detection, and the mean number of reads per cell (324 000) may have been inadequate for CNV calling.
DCV with increased DNA content in AD has been reported by three groups. The study showing APP gains, performed by the group which had originally described DCV, found a 8% increase in DNA content of AD frontal cortical nuclei compared to controls [69] . Another group showed that neurons with higher DNA content were preferentially lost in AD [112] , and the increased DNA content in AD was highest in the most vulnerable cortical areas [113] . In a study of DLB and controls, DNA content increase in the cortex and hippocampus correlated with Alzheimer pathology [108] . Because of the presence of APP on chromosome 21, and the increased incidence of AD in trisomy 21, aneusomy of this chromosome has been of particular interest, and could contribute to DCV. One study reported excess chromosome 21 aneusomy in AD frontal cortical neurons against controls (10.7% v 1.7%), although losses were almost as common as gains [114] . Another early study showed no difference in disease and control brains, although a surprisingly high aneusomy level was claimed [46] . More recent studies of single neurons did not find excess chromosome 21 aneusomy in Alzheimer [69] , including by single-cell WGS [49] . It thus appears that the increase in APP copy number, and in DNA content overall, in AD cortex, is not primarily due to chromosome 21 aneusomy. Interestingly, these gains might not arise in embryogenesis. One hypothesis of AD pathogenesis considers aberrant cell cycle reentry, with DNA synthesis in a nondividing neuron [69] ultimately leading to apoptosis, as an early event [115] . DNA damage has been reported in early AD [116] , with evidence of deficient DSB repair [117] , and this could trigger cell cycle re-entry [118] . An intriguing finding, potentially linking AD to mosaicism outside the CNS, is the mosaic loss of chromosome Y (LOY) in PBL throughout lifetime, associated with shorter survival and increased risk of cancer [119] . AD males showed a higher LOY compared to controls, and prospectively men with LOY mosaicism in PBL had greater risk of being diagnosed with AD later [120] . Defects in immune surveillance were proposed to underlie this association.
Other sporadic neurodegenerative diseases
An early study of cerebral cortex DNA, the first looking for somatic mutations in a neurodegenerative disease to our knowledge, did not find any somatic SOD1 mutations [121] . We are not aware of any somatic mutation in a known ALS gene, on an inherited normal allele, causing sporadic disease, although the special case of C9ORF72 is discussed in the next section. WGS of PBL DNA in monozygotic twins discordant for ALS did not reveal any relevant somatic mutations [122] , although interestingly epigenetic modifications were recently reported [123] . There has been one report of a sporadic case of Creutzfeldt-Jakob disease with a known disease-causing mutation which was absent in the parents, and appeared to be a somatic event [124] . This was estimated at a level of 97% in PBL and brain, and must have therefore arisen in one of the first postzygotic cell divisions (and presumably undergone positive selection to reach such a level). The alternative possibility, of a partial sample contamination, with the mutation actually arising in the parental germline, cannot be excluded.
A possible role for glia
Glia have been studied less, despite their likely importance in neurodegeneration. Glial aneuploidy was reported to increase with age in mouse cortex [125] . The existence of neurodegeneration in histiocytosis prompted a mouse study of a somatic mutation in the B-raf proto-oncogene introduced in the microglial lineage. Remarkably, this led to a severe late-onset neurodegenerative disorder [126] .
Somatic mutations in genes causing rare genetic neurodegenerative diseases
There are numerous rare familial neurodegenerative conditions, such as hereditary spastic paraplegia (HSP), with some cases with no family history [127] . In addition to recessive inheritance, incomplete penetrance, and de novo mutations arising in meiosis, another possibility is that the unaffected parent is a mosaic [5] . This was documented in a family with spastin-related HSP, where the unaffected mother had mosaicism in her PBL, and presumably germline, DNA [128] . This is similar to the AD case discussed, although the mosaic parent there had been affected [110] . A further twist in Xlinked dominant disorders, such as a form of neurodegeneration with brain iron accumulation, is that males with severe mutations may only be viable if they are mosaics [129] .
Somatic mutations as a mediator or modifier in inherited neurodegenerative diseases
MAPT mutations underlie a subset of FTLD. Peripheral tissues (fibroblasts, PBLs and lymphoblasts) from patient carrying MAPT mutations had somatic chromosomal aberrations [130] , and two transgenic mouse models had excess aneuploidy in PBLs, although the brain was not studied [131] . In Drosophila tauopathy models, the 4-repeat tau protein isoform expression affected mitosis, inducing chromosomal missegregation and higher levels of aneuploidy in neuronal tissue [132] . Studies of human brains with MAPT mutations will be needed to confirm these intriguing findings.
Expansion of microsatellite repeats underlies many inherited neurodegenerative disorders including Huntington's disease (HD), several spinocerebellar ataxias and ALS/FTLD caused by C9ORF72 expansions. The inherent instability of such repeats has prompted a search for somatic instability leading to mosaicism, which has been found in HD, and several other CAG repeat disorders [133] . In HD, the inherited repeat length correlates with the chance of somatic expansion [134] . The age of onset variability is not fully explained by the inherited repeat size, and the expansion size in the prefrontal cortex also correlates with onset age [135] . Somatic instability is tissue-specific, with the cerebellum apparently spared [135] , and the striatum particularly affected, which may explain the differential vulnerability [136] . The somatic instability appears to be due to DNA damage and errors in repair in postmitotic neurons [137] . Remarkably, suppression of somatic instability delayed the phenotype in a mouse model [138] . In GWAS analysis of CAG repeat disorders as a whole, DNA repair genes were associated with onset age, further suggesting the importance of somatic expansion [133] . Somatic instability may influence the rate of progression, with a coding MSH3 variant having the strongest association in a GWAS [139] . MSH3 is a neuron-specific gene for DNA mismatch repair, already implicated in the regulation of somatic instability in HD mouse models, and in patients with a different expansion disorder, myotonic dystrophy type 1 [140] . These data point to a mechanism whereby HD is modified and exacerbated by both the inherent somatic instability of the causative mutation, and inherited alleles which influence the somatic mutation burden. It is plausible that reduced penetrance alleles in HD (36-39 repeats), and intermediate alleles (27-35 repeats) , which may cause disease very rarely [141] , become pathogenic only when expanded in the striatum. This could apply to other CAG repeat disorders. In a case of MSA with additional SCA17 pathology and an intermediate expansion size of 41, however, no evidence of further somatic expansion was found [142] .
In ALS, the repeat expansion in C9ORF72 is somatically unstable, when an expanded allele is present already [143, 144] . The variable phenotype caused by C9ORF72 expansions could be due to different patterns of somatic expansion [145] . In a study of multiple tissues in a series with and without pathogenic expansions [144] , there were two cases with modest expansions in PBL and extreme ones in CNS (highly variable, up to 3500). Given their incomplete penetrance, small or borderline expansions may only be pathogenic if they expand somatically in the CNS. Sporadic cases could be due to de novo somatic expansions from an allele with a normal repeat length, in which case testing of PBL might not reveal the expansion if it was limited to the brain, or ectoderm. However, repeats sizes up to 15 appear stable [144] , consistent with an earlier suggestion that pathogenic mosaicism may not arise from a truly normal allele [146] .
Several inherited DNA repair disorders have neurological phenotypes [16, 34] . Although severe DNA damage leads to early cell loss and microcephaly, progressive neurodegeneration also occurs in some of these, with ataxia as the common feature, suggesting that these DNA repair pathways may be most important in the cerebellum. Ataxia-telangiectasia (AT) is caused by mutations in ATM, which lead to defective DNA repair, particularly affecting DSBs. Patients usually develop cancer and progressive neurodegeneration, most prominent in the cerebellum. Excess aneuploidy has been reported in AT brains [147] . Disorders of DSB repair dysfunction with neurodegeneration include Xeroderma Pigmentosum (XP) and Cockayne Syndrome (CS). XP has more neurodegeneration in general, except for the cerebellum, where neuronal loss is more severe in CS [148, 149] . The pathogenesis of ataxia with oculomotor apraxia 2, and the related ALS4, may also involve impaired DSB repair and other deficiencies of genome maintenance [150] . In ataxia with oculomotor apraxia 1, SSB repair is affected [34] . Firm conclusions on how the DNA repair deficit leads to neurodegeneration require detailed sequencing studies of affected brains, to determine whether the main driver are mutations resulting from aberrant repair, or apoptosis as a direct result of DNA damage [151] . The former explanation is supported by very recent work showing greater than twofold age-adjusted increase in single neuron SNVs in CS and XP [71] . Another possibility, at least for AT, is compromise of a different protein function altogether [152] . Interestingly, ALS caused by mutations in FUS also belongs here, as the protein is involved in DSB repair, and patients had significantly higher levels of DNA damage in motor cortex compared to controls [153] . Finally, progranulin, a cause of familial FTLD with variable phenotypes, also appears to regulate a DNA repair pathway [154] .
Could proteins involved in neurodegeneration cause somatic mutations?
We have focused on the possibility of somatic mutations contributing to neurodegeneration. The reverse question is whether protein aggregation, inflammation and other processes occurring during neurodegeneration, can cause DNA damage, and somatic mutations in postmitotic neurons. DNA breaks induced by neuronal activity in mice were higher in APP transgenic mice, and potentiated by Ab oligomers in neuronal cultures [35] . Tau oligomers damaged DNA in hippocampal neurons from transgenic mice [155] , and alpha-synuclein caused DNA breaks in human cell models [156] . The idea of accumulating protein oligomers leading to somatic mutations is tantalizing, but requires further evidence.
Conclusions, study design considerations and future directions
The evidence of mosaicism in apparently healthy brain tissue has increased rapidly in recent years. The ultimate cause of sporadic neurodegenerative disease remains partly unexplained. We have discussed the theoretical basis and evidence so far for a role of somatic mutations in neurodegenerative disorders. Somatic expansion can clearly influence the phenotype of inherited expansion repeat disorders. The real challenge is to determine how much of a role somatic mutations may have in predominantly sporadic disorders like PD, AD and ALS. The evidence so far is stronger in Alzheimer's, with common APP somatic CNVs and rare potentially relevant SNVs, but there is still only one case which was proven to be due to a somatic mutation [110] , and the APP copy number gains in sporadic AD have not been fully defined [69] . If age of onset and/or severity corresponds to the somatic mutation burden [7, 14] , younger and more severe patients should be studied, but they may, however, also be the ones most likely to carry inherited risk alleles, confounding the picture. Clear-cut cases, where a particularly detrimental somatic mutation essentially causes the disease, may be relatively rare. If, however, somatic mutations in relevant genes are relatively common, even at low or modest levels, they may act as risk factors, alongside inherited risk alleles, and any epigenetic and environmental influences. The origin and distribution of the mutation(s) could determine the phenotype and age of onset, with late or low level mutations perhaps clinically silent (Figure 2) .
Study design should depend on the mutation type and level being sought. If somatic mutations are seen as potential initiators of spread, rather than determinants of regional vulnerability, very low levels may be relevant. Targeted detection of low level SNVs can be optimized by use of 'molecular barcodes' to minimize PCR artefacts [157] . For postmitotic changes, single neuron strategies appear mandatory. Although single neuron WGS has revolutionized the field, deep WGS of hundreds of single neurons from multiple cases and controls is beyond the reach of most labs. Large-scale collaborations, such as the Brain Somatic Mosaicism Network for neurodevelopmental and neuropsychiatric disorders [11] , are the likely answer. As discussed earlier, the technical and bioinformatics aspects require further development, as orthogonal validation in DNA from a single neuron is essentially impossible once it has been amplified. New WGA methods may minimize artefacts and uneven amplification [73, 158] . Fluorescence-activated sorting has been used to isolate nuclei from specific neuron types, although laser-capture can select neurons in their proper spatial location [40] , and was indeed used for targeted SOD1 sequencing in cortical motor neurons [159] . Sorting methods can also be used to isolate pools of specific cell types [11] .
An important 'elephant in the room' is the fact that the likely consequence of a detrimental somatic mutation is the death of the neuron carrying it, before the death of the individual, unlike cancer, where a mutation would lead to clonal proliferation. The absence of somatic mutations in an end-stage brain may simply be a result of loss of the cells carrying them. This has been illustrated in AD, where neurons with increased DNA content are preferentially lost [112] , and HD, where large somatic gains are present in the cortex, but not the striatum, where somatic instability is pronounced, but neurons are inherently more vulnerable to CAG expansions [136] . Analysing autopsy cases with short disease duration may ensure that some neurons with relevant somatic mutations are still present. Utilizing healthy individuals with incidental autopsy findings, such as incidental Lewy body disease which may represent preclinical PD [160] , is another strategy, but these individuals might have never developed the disease clinically.
The brain region chosen is also a matter for discussion. It would intuitively make sense to analyse the brain region or cell type affected earliest, or most severely, yet this may be where mutation-carrying vulnerable cells do not survive. Using an alternative region, where the cells are resistant to the effects of mutations in inherited cases (e.g. cerebellum in familial PD), might help, but only if the mutation(s) occurred in a shared lineage. Tissues accessible during life, which could be used as biomarkers, are worth considering, such as salivary glands in PD [161] . CSF could also be a source of DNA from dying neurons [162] . An often neglected easily accessible source of ectodermal DNA are hair follicles [163] (Figure 1 ). Comparison of DNA from different This may depend on the somatic mutation overall burden, which will be influenced by the timing of their occurrence, but also selective pressures. The likelihood of each outcome, from severe disease to no pathological changes, is represented by the width of each arrow. This may be on a continuum, influenced by the mutation burden, and their functional consequence, but also by inherited risk alleles, epigenetic changes and any environmental factors. Even if somatic mutations contribute to a disease, it could still arise in cases with none, due to other risk factors. germ layers is often helpful, and if no blood is available, meninges can be used as a source of mesodermal DNA.
In conclusion, somatic genomic variation in the brain is increasingly recognized. We have discussed the theoretical considerations regarding a role of somatic mutations in neurodegeneration, especially in sporadic cases where the ultimate cause or trigger remains largely unproven, and presented the emerging evidence in Alzheimer's. There is clear need for investment into considering the contribution of somatic mutations to disorders which are becoming more frequent as the population ages. Large studies, coupled with improvements in single-cell sequencing, are required for reliable estimation of the somatic mutation burden in healthy and diseased brains.
Note added
A very recent study of clonally expanded human foetal forebrain cells has shown 200-400 SNVs in each. The mutation rate during neurogenesis was estimated at 5.1 per day per progenitor, and was higher than in the first few cell divisions [164] .
